Finance

Lists
Q1 2027 earnings • released • Revenue miss -4.98%
See results
STAR:NSE
Strides Pharma Science Ltd
₹1,030.00
-3.99%
(-42.80) 1D
Jul 31, 3:30:03 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
₹1,073.60
High
₹1,100.00
Low
₹1,011.10
Mkt. cap
94.94B
Avg. vol.
142.52K
Volume
1.70M
Dividend
0.49%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
17.07
52-wk high
₹1,231.00
52-wk low
₹768.65
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
4K
Open
₹1,073.60
High
₹1,100.00
Low
₹1,011.10
Mkt. cap
94.94B
Avg. vol.
142.52K
Volume
1.70M
Dividend
0.49%
Quarterly dividend
₹1.25
Ex-dividend date
Jul 31, 2026
P/E ratio
17.07
52-wk high
₹1,231.00
52-wk low
₹768.65
EPS
₹60.34
Shares outstanding
89.55M
No. of employees
4K
News stories
From sources across the web
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3.54K
Founded1990
HeadquartersBengaluru, Karnataka, India
SectorPharmaceutical industry
Websitestrides.com
Last report
Jul 31, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
- / -
Revenue / Est. (INR)
12.65B / 13.32B
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
12.21B
11.95B
13.23B
12.65B
Cost of goods sold
5.15B
4.63B
7.19B
-
Cost of revenue
5.15B
4.63B
7.19B
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.27B
2.30B
3.45B
-
Operating expense
5.24B
5.46B
4.91B
-
Total operating expenses
10.39B
10.09B
12.10B
-
Operating income
1.82B
1.85B
1.13B
-
Other non operating income
271.40M
1.07B
-1.66B
-
EBT including unusual items
1.53B
2.45B
1.48B
-
EBT excluding unusual items
1.62B
2.49B
502.07M
-
Income tax expense
215.93M
373.53M
187.70M
-
Effective tax rate
14.10%
15.22%
12.68%
-
Other operating expenses
2.47B
2.66B
928.53M
-
Net income
1.28B
2.02B
1.27B
-
Net profit margin
10.45%
16.92%
9.59%
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
404.82M
-
Interest expense
-461.27M
-433.79M
-130.82M
-
Net interest expenses
-461.27M
-433.79M
274.00M
-
Depreciation and amortization charges
496.43M
506.23M
532.49M
-
EBITDA
2.31B
2.25B
1.55B
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps